| Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer I Davis, R Zielinski New England Journal of Medicine, 2019 | 1221 | 2019 |
| ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate … ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... N Engl J Med 381 (2), 121-131, 2019 | 115 | 2019 |
| Targeting the apoptosis pathway in prostate cancer RR Zielinski, BJ Eigl, KN Chi The Cancer Journal 19 (1), 79-89, 2013 | 78 | 2013 |
| Virtual reality as a patient education tool in healthcare: a scoping review SR van der Kruk, R Zielinski, H MacDougall, D Hughes-Barton, KM Gunn Patient Education and Counseling 105 (7), 1928-1942, 2022 | 65 | 2022 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 59 | 2023 |
| Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ID Davis, AJ Martin, RR Zielinski, A Thomson, TH Tan, S Sandhu, ... Journal of Clinical Oncology 40 (17_suppl), LBA5004-LBA5004, 2022 | 45 | 2022 |
| Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021 SR Van Der Kruk, P Butow, I Mesters, T Boyle, I Olver, K White, ... Supportive Care in Cancer, 1-44, 2022 | 41 | 2022 |
| A ustralian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel M Alexander, J King, A Bajel, C Doecke, P Fox, S Lingaratnam, JD Mellor, ... Internal medicine journal 44 (10), 1018-1026, 2014 | 41 | 2014 |
| Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy CJ Sweeney, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... European Urology 80 (3), 275-279, 2021 | 38 | 2021 |
| Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer R Zielinski, KN Chi Future Oncology 8 (10), 1239-1251, 2012 | 30 | 2012 |
| Consensus minimum data set for lung cancer multidisciplinary teams: results of a Delphi process E Stone, N Rankin, J Phillips, K Fong, DC Currow, A Miller, G Largey, ... Respirology 23 (10), 927-934, 2018 | 28 | 2018 |
| Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP MR Stockler, AJ Martin, ID Davis, HM Dhillon, SD Begbie, KN Chi, ... Journal of Clinical Oncology 40 (8), 837-846, 2022 | 24 | 2022 |
| Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians G Chazan, F Franchini, M Alexander, S Banerjee, L Mileshkin, P Blinman, ... ESMO open 5 (6), e001090, 2020 | 23 | 2020 |
| Implementation of the Australasian Teletrial Model: lessons from practice S Sabesan, J Zalcberg, C Underhill, R Zielinski, K Burbury, Z Ansari, ... Asia Pac J Clin Oncol 15 (Suppl 8), 3-14, 2019 | 18 | 2019 |
| Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC … C Sweeney, AJ Martin, RR Zielinski, A Thomson, TH Tan, SK Sandhu, ... J Clin Oncol 37, LBA2, 2019 | 16 | 2019 |
| Systematic Review of Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer C Cao, A Guo, C Chen, A Chakos, M Bott, CFJ Yang, R Zielinski, F Melfi Seminars in thoracic and cardiovascular surgery 33 (3), 850-857, 2021 | 14 | 2021 |
| Retrospective evaluation of the use of Pembrolizumab in malignant mesothelioma in a real-world Australian population T Ahmadzada, WA Cooper, M Holmes, A Mahar, H Westman, AJ Gill, ... JTO Clinical and Research Reports 1 (4), 100075, 2020 | 12 | 2020 |
| Efficacy and mechanisms of biventricular and left/right direct cardiac compression in acute heart failure sheep GL Gallagher, Y Huang, S Morita, RR Zielinski, SN Hunyor Artificial Organs 31 (1), 39-44, 2007 | 12 | 2007 |
| Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international … J Santucci, M Tacey, B Thomson, M Michael, R Wong, J Shapiro, ... European Journal of Cancer 174, 102-112, 2022 | 11 | 2022 |
| Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences EB Moth, BE Kiely, A Martin, V Naganathan, S Della-Fiorentina, ... Journal of Geriatric Oncology 11 (4), 626-632, 2020 | 10 | 2020 |
